All UK companies at BIO-Europe Spring 2013

UK companies attending BIO-Europe Spring 2013 as part of the official delegation

(Click here to search profiles by company type or keyword)

UK stand (Booth 41)
BIA (UK BioIndustry Association), Domainex, Entrepreneurs Fund, Epistem, Fusion Antibodies, Innova Biosciences, Novozymes Biopharma, Ockham Oncology, Oxford BioMedica, Patheon (UK), Phynova, Physiomics plc, Reach Separations, Selcia, XenoGesis

Exhibitors
BioPartner.co.uk, UK stand (Booth 41)
Almac Group  (Booth 45)
cddi (Booth 54)

UK companies associated with the delegation*:
Alcyomics, AMRI Global, Atebion-BDS, Autifony Therapeutics, Bicycle Therapeutics, BioMoti, College Hill Life Sciences, Coulter Partners, Crescendo Biologics, Critical Pharmaceuticals, CrystecPharma, e-therapeutics, Edinburgh BioQuarter, Hologic GenProbe, Illetrop, Immupharma, Kymab, Osborne Clarke, PharmaTelevision, PharmaVentures, Polytherics, Present Value, ProImmune, Psioxus Therapeutics, Reneuron Group, Regulatory Resource Group (RRG), Sachs Associates, Sera Laboratories, Simbec Research, Sygnature Discovery, UKTI East of England, UKTI Inward Investment Organisation, Vivacta, Warner Chilcott, Welsh Government

All attending UK companies (146):
3M Drug Delivery Systems, A. A. Thornton & Co, Abingworth, Acellera, Alcyomics, Almac Discovery, Almac Sciences, AMRI Global, Antitope, Apex Healthcare Consulting, Aptiv Solutions, Aquapharm Biodiscovery Ltd, Argenta Discovery 2009 Ltd, AstraZeneca, Atebion-BDS, Autifony Therapeutics, Avillion, Biocatalysts, Biomoti, BioPartner.co.uk, Biopharm Insight, Brainwave-Discovery, Bristol-Myers Squibb, Cancer Research Technology, Catalent, cddi, Charles River, Chugai Pharma Marketing, Circassia, Clinical Reference Laboratory, Cmed Clinical Services, Cobra Biologics, College Hill, Coulter Partners, Covance, Creabilis, Creative Value & Vision, Crescendo Biologics, CrystecPharma, Current Partnering, Cyclacel Pharmaceuticals, Cytox, Domainex, Dr Reddy's, Edinburgh BioQuarter, Eisai Europe, Epistem, ERA Consulting (UK) Ltd., Ergomed Clinical Research, e-Therapeutics plc, Eurofins, European Regulatory Solutions, Ferghana Partners, Fujifilm Diosynth Biotechnologies, Fusion Antibodies, george james, GlaxoSmithKline, GlobalData, GW Pharmaceuticals, Harlan Laboratories, Heptares Therapeutics, Hologic Gen-Probe, Huntingdon Life Sciences, Illetrop, ImmuPharma plc, Innova Biosciences, Institute of Cancer Research, Kilburn & Strode, KWS BioTest, Kymab Ltd, Laurantis Pharma, Medius Associates, Medtrack, Merge, Merge Healthcare, Mewburn Ellis LLP, MINA Therapeutics, Mundipharma International, MVM Life Science Partners, Nature Publishing Group, Norgine, Novella Clinical, Novozymes Biopharma, Novozymes Biopharma, OBN (UK), One Nucleus, Ono Pharma UK, Oxford BioMedica plc, Oxford BioTherapeutics, Oxford Pharmascience Group Plc, Oxyrane, Pangolin Pharmatech, Patheon (UK), Pharmalicensing, PharmaTelevision, PharmaVentures, Phynova Group, Physiomics plc, Phytopharm plc, PolyTherics, Present Value, Present Value Ltd, Probe Scientific, Proimmune, Proximagen, PsiOxus Therapeutics, Qiagen, Quintiles, R&D Focus, Regulatory Resource Group (RRG), Richard Hayhurst Associates, Russlan Clinical Research, Sachs Associates, Sage Healthcare, Scottish Development International, Selcia, Sera Laboratories International, Shionogi Limited, Simbec Research, Sistemic, Strathclyde University, Sygnature Discovery, Syne qua non, Synpromics, Teijin Pharma, Teva UK, Theradex Europe, Theryte, Therapeutic Challenges Analysis, Thomson Reuters, Vivacta, Warner Chilcott UK, Warwick Ventures, Welsh Government, XenoGesis, Xention.

Join them here!

*BioPartnership Programme members are hyperlinked